Research programme:protein stabilisation small molecule therapeutics - Stablix Therapeutics/Vertex Pharmaceuticals
Latest Information Update: 23 May 2023
At a glance
- Originator Stablix Therapeutics; Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified